Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation.
Research output: Journal contributions › Journal articles › Research › peer-review
Standard
Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. / Roos, Anna-Karin ; Moreno, Sonia; Leder, Christoph et al.
In: Molecular Therapy, Vol. 13, No. 2, 01.02.2006, p. 320-327.Research output: Journal contributions › Journal articles › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation.
AU - Roos, Anna-Karin
AU - Moreno, Sonia
AU - Leder, Christoph
AU - Pavlenko, Maxim
AU - King, Alan
AU - Pisa, Pavel
N1 - Funding Information: This work was supported in part by the Cancer Society in Stockholm, the Karolinska Institutes Fund, the Swedish Cancer Society, the EU 6-FP ALLOSTEM (LSHB-CT-2004-502219), and the U.S. Department of Defense Prostate Cancer Research Program (PC030958).
PY - 2006/2/1
Y1 - 2006/2/1
N2 - Recently it has become clear that more potent methods for DNA vaccine delivery need to be developed to enhance the efficacy of DNA vaccines. In vivo electroporation has emerged as a potent method for DNA vaccine delivery. In a mouse model, we evaluated the CD8(+) T lymphocyte response to a prostate cancer DNA vaccine encoding prostate-specific antigen (PSA) after intradermal electroporation. A significantly increased gene expression (100- to 1000-fold) and higher levels of PSA-specific T cells, compared to DNA delivery without electroporation, was demonstrated. Interestingly, investigation of a panel of different electroporation conditions showed that only some conditions that induce high levels of gene expression additionally induced cellular immunity. This suggests that electroporation parameters should be carefully optimized, not only to enhance transfection efficiency, but also to enhance the immune response to the vaccine. This study demonstrates the applicability of intradermal electroporation as a delivery method for genetic cancer vaccines and other DNA vaccines relying on antigen-specific T cell induction.
AB - Recently it has become clear that more potent methods for DNA vaccine delivery need to be developed to enhance the efficacy of DNA vaccines. In vivo electroporation has emerged as a potent method for DNA vaccine delivery. In a mouse model, we evaluated the CD8(+) T lymphocyte response to a prostate cancer DNA vaccine encoding prostate-specific antigen (PSA) after intradermal electroporation. A significantly increased gene expression (100- to 1000-fold) and higher levels of PSA-specific T cells, compared to DNA delivery without electroporation, was demonstrated. Interestingly, investigation of a panel of different electroporation conditions showed that only some conditions that induce high levels of gene expression additionally induced cellular immunity. This suggests that electroporation parameters should be carefully optimized, not only to enhance transfection efficiency, but also to enhance the immune response to the vaccine. This study demonstrates the applicability of intradermal electroporation as a delivery method for genetic cancer vaccines and other DNA vaccines relying on antigen-specific T cell induction.
KW - Biology
KW - electroporation
KW - Prostate-specific antigen
KW - DNA vaccine
KW - CTL
KW - immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=30344433748&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/52c38cd3-dedb-3239-8483-bfe43f590098/
U2 - 10.1016/j.ymthe.2005.08.005
DO - 10.1016/j.ymthe.2005.08.005
M3 - Journal articles
VL - 13
SP - 320
EP - 327
JO - Molecular Therapy
JF - Molecular Therapy
SN - 1525-0016
IS - 2
ER -